Eugene Park, MD
Urology · Petersburg, VANPI 1992707137
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (50.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Intuitive Surgical at 53.3% of the total. 2025 is the largest year on record at $8,720, more than ten times the $783 reported in 2019.
Across 145 payments — averaging $112.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- Richard Wolf Medical Instruments Corp.$4K
- AbbVie$541
- Astellas Pharma US Inc$458
- Bayer$325
- Blue Earth Diagnostics$262
- plus $2K from 33 others
What the payments were for
- Consulting fees$3,50021%
- Travel & lodging$1,0847%
- Food & beverage$3,55822%
- Education$8,16450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $8,697 |
| Richard Wolf Medical Instruments Corp. | 3 | $4,399 |
| AbbVie(2 entities) | 25 | $541 |
| Astellas Pharma US Inc | 17 | $458 |
| Bayer | 10 | $325 |
| Blue Earth Diagnostics | 9 | $262 |
| Gilead | 1 | $147 |
| Amgen | 1 | $125 |
| Johnson & Johnson(2 entities) | 5 | $114 |
| Myovant Sciences Inc. | 4 | $90 |
| Axonics, Inc. | 5 | $82 |
| Laborie Medical Technologies Corp. | 2 | $82 |
| Sumitomo Pharma America, Inc. | 4 | $81 |
| Biohaven Pharmaceuticals, Inc. | 3 | $75 |
| Novo Nordisk | 5 | $69 |
| Rochester Medical Corporation | 4 | $67 |
| Urovant Sciences Inc | 3 | $64 |
| Antares Pharma, Inc. | 3 | $53 |
| Lilly USA, LLC | 3 | $53 |
| Dendreon Pharmaceuticals LLC | 2 | $51 |
| Coloplast | 3 | $51 |
| Pfizer | 4 | $49 |
| Urogen Pharma, Inc. | 2 | $41 |
| Endo Pharmaceuticals Inc. | 3 | $36 |
| Ambu Inc. | 1 | $32 |
| Bard Access Systems, Inc. | 1 | $30 |
| Myriad Genetic Laboratories, Inc. | 2 | $29 |
| Covidien LP | 1 | $24 |
| AstraZeneca | 2 | $24 |
| Merck | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Progenics Pharmaceuticals, Inc. | 1 | $18 |
| Smith+Nephew | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Innovation Technologies Inc | 1 | $14 |
| Olympus America Inc. | 1 | $13 |
| Forte Bio-pharma LLC | 1 | $12 |
| GSK | 1 | $12 |
| Tolmar Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$8,651
- Medical Instrumentation$4,377
- Nubeqa$129
- KRYSTEXXA$125
- XTANDI$117
- BOTOX$117
- Axumin$113
How this compares
$16,307 in reported general payments places this provider in the 85th percentile of 300 urology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 16 | $216,088 |
| Tolterodine Tartrate ErTolterodine Tartrate | 34 | $3,440 |
| Tamsulosin Hcl | 226 | $2,529 |
| Bethanechol Chloride | 15 | $1,330 |
| Finasteride | 137 | $1,306 |
| Methenamine Hippurate | 16 | $1,214 |
| Oxybutynin Chloride ErOxybutynin Chloride | 46 | $1,124 |
| Solifenacin Succinate | 33 | $1,071 |
| Dutasteride | 26 | $694 |
| Testosterone Cypionate | 14 | $475 |
| Ciprofloxacin Hcl | 69 | $427 |
| Cephalexin | 46 | $424 |
| Silodosin | 13 | $383 |
| Doxycycline Hyclate | 28 | $352 |
| Doxazosin Mesylate | 11 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $325 | $216,08816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 300 urology providers in Virginia.
Other urology in Petersburg
- Michael FabrizioVirginia Beach$1.5M
- Gregg EureVirginia Beach$1.4M
- Jessica DelongVirginia Beach$578K
- Robert GivenVirginia Beach$157K
- Michael WilliamsVirginia Beach$144K
- Nilay GandhiWoodbridge$138K
- Shawn MarhamatiWoodbridge$130K
- Patrick WhelanSuffolk$114K
- Jennifer Miles-ThomasVa Beach$101K
- Charles DanielRoanoke$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.